Patients and methods: Data were pooled from three large prospective trials (one single-arm and two randomized versus chemotherapy) of crizotinib in patients with ALK-positive NSCLC determined by Vysis ALK Break Apart FISH using a cut-off of 15% ALK-positive cells. Logistic regression and proportional hazards regression analyses were used to explore the association of percent ALK-positive cells with objective response and progression-free survival (PFS), respectively.
Introduction
Patients with advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) treated with crizotinib experience a high response rate and prolonged progression-free survival (PFS) [1] [2] [3] . In clinical studies of crizotinib, ALK status was determined using fluorescence in situ hybridization (FISH), where 15% of tumor cells demonstrating a pattern of ALK probe hybridization indicative of gene rearrangement was considered to meet the criteria for defining ALKpositive NSCLC. The 15% cut-off was not originally defined by a clinical end point; rather, it was based on an analytical assessment of the background signal in tissues lacking ALK gene rearrangement [4] . Assessment of the clinical utility of the 15% FISH cutoff and its relationship to clinical outcomes has been limited by the small number of patients with ALK-positive NSCLC near the 15% ALK-positive cut-off [4] [5] [6] .
The present analysis combined data from three large clinical trials of crizotinib in ALK-positive NSCLC to address the following objectives: (i) to describe the distribution of the percentage of malignant cells positive for ALK gene rearrangement by FISH in a screened population of patients with NSCLC; (ii) to explore the association of the percentage of ALK-positive cells by FISH with objective response and PFS in a pooled population of crizotinibtreated patients with FISH scores of 15%; and (iii) to explore the association of the percentage of ALK-positive cells by FISH with magnitude of difference in objective response and PFS between treatment arms in pooled randomized trials of crizotinib versus chemotherapy among patients with FISH scores of 15%.
Results from these analyses expand our understanding of ALK FISH testing as a companion diagnostic test to appropriately identify patients with NSCLC who may benefit from treatment with crizotinib.
Methods Patients
Data were pooled from three trials of patients with ALK-positive NSCLC (PROFILE 1005, PROFILE 1007, and PROFILE 1014). PROFILE 1005 (NCT00932451) was a phase II, single-arm trial of crizotinib in previously treated patients with ALK-positive NSCLC. PROFILE 1007 (NCT00932893) was a phase III, randomized, open-label trial of crizotinib versus pemetrexed or docetaxel in the second-line setting. PROFILE 1014 (NCT01154140) was a phase III, randomized, open-label trial of crizotinib versus pemetrexed in combination with either carboplatin or cisplatin in the first-line setting.
Data were analyzed using two approaches: (i) pooling data for crizotinib-treated patients across all studies (PROFILE 1005, 1007, and 1014) and (ii) pooling data for crizotinib-treated and chemotherapy-treated patients in the randomized trials (PROFILE 1007 and 1014). Efficacy data were only available for ALK-positive patients.
FISH analysis
FISH analysis was carried out at designated central laboratories using the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular, Des Plaines, IL, USA). Evaluation of ALK FISH slides, signal enumeration, and disposition of cells as positive or negative for ALK gene rearrangement was carried out as described in the test package insert. A sample was considered negative if <5 of 50 cells were scored as positive for gene rearrangement by defined signal enumeration criteria, and positive if >25 of 50 cells scored as positive. For samples that were equivocal (i.e. 5-25 of 50 cells scored as positive), an additional 50 cells were enumerated and the sample was considered positive if the average percent of positive cells for the two scoring assessments was 15% [5] .
Efficacy analyses
Tumor response was determined per Response Evaluation Criteria in Solid Tumors version 1.1; objective responses were confirmed, and only confirmed responses were included in the analysis. Unless death occurred within 42 days of starting treatment (early death), patients with inadequate baseline tumor assessments or no on-treatment tumor assessments were classified as having an indeterminate response. Statistical analyses of tumor response were conducted on both all treated patients and those with adequate baseline assessments; results were comparable between analyses. Data from the analysis of patients with adequate baseline assessments are presented here.
For PFS analysis, patients with inadequate baseline tumor assessments were censored on day 1. For patients with no on-treatment assessments, censorship was on day 1 unless death occurred within 14 weeks (in which case the death was an event). Statistical analyses of PFS were conducted on all treated patients only, since additional analyses excluding patients without adequate baseline assessments were not necessary for this end point.
Statistical analysis
Odds ratios and v 2 tests were used to examine the effect of increasing the percent-positive cut-off to define positivity on objective tumor response; a test for significance due to Miller and Sigmund [7] was applied to adjust for the multiple tests. Hazard ratios (HRs) and log-rank tests were used to examine the effect of increasing the percent-positive cut-off to define positivity on PFS. A Bonferroni adjustment was applied for the pooled analysis.
Logistic regression analysis was carried out to assess the association of objective response with the percentage of ALK-positive cells; a proportional hazards regression model was used to assess the association of PFS with the percentage of ALK-positive cells. For models of crizotinibtreated patients only, covariates were the number of prior systemic therapies (0, >0 for pooled, 1; >1 for PROFILE 1005 and 1007; not included for PROFILE 1014) and percentage of ALK-positive cells (continuous variable). For analysis of the randomized trials, treatment [crizotinib or control (chemotherapy)] and interaction (treatment indicator X percentage of ALK-positive cells) terms were also included in the models along with the above-noted covariates.
Results

Patients
A total of 11 081 patients were screened for ALK status. Of 1958 patients (18%) who were ALK positive, 1454 were enrolled in one of the three PROFILE studies (74% of all ALK-positive patients). Of these, 1449 were treated and 1357 received crizotinib, which included 247 patients who received crizotinib after crossing over from the control arm in the randomized trials (supplementary Figure S1 , available at Annals of Oncology online).
Patient demographics were generally comparable across the percentage ranges of ALK-positive cells, although lower percentage ranges of ALK-positive cells were observed in a higher proportion of Asian patients when compared with Caucasian patients (supplementary Table S1 , available at Annals of Oncology online).
Distribution of the percentage of ALK-positive cells
Of the 1454 patients enrolled in one of the three PROFILE studies, the median percentage of ALK-positive cells was 58% [mean (standard deviation), 59% (22%); range 15%-100%; Figure 1 ]. Of the enrolled ALK-positive patients, 5% (n ¼ 72) were within 5% points of the 15% cut-off defining ALK-positive status (i.e. 15%-19%). A total of 7512 patients were ALK negative (68%), with a median percentage of ALK-positive cells of 2% [mean (standard deviation), 3% (3%); range 0%-14%; Figure 1 ]. Of these, 2% (n ¼ 129) were within 5% points of the <15% cut-off defining negative status (i.e. 10%-14%).
Analysis of the association of the percentage of ALK-positive cells with clinical outcomes in crizotinib-treated patients
Tumor response as a function of the percentage of ALK-positive cells. The objective response rate (ORR) for all ALK-positive crizotinib-treated patients was 55%. When evaluated by subgroups based on the percentage of ALK-positive cells, the ORR for all crizotinib-treated patients with adequate baseline assessments was similar across subgroups except at the low end of the distribution of the percentage of ALK-positive cells (Table 1 ). The ORR estimate was lowest at 38% [95% confidence interval (CI) 26-51] in the subgroup of patients (n ¼ 66) who had a percentage of ALK-positive cells near the 15% cut-off (15%-19%; Table 1 ). Within this subgroup, patients with exactly 15% ALK-positive cells (n ¼ 19) had an ORR of 37% (95% CI 16-62).
In a logistic regression analysis of crizotinib-treated patients, covariates of no prior systemic therapy for advanced disease and a higher percentage of ALK-positive cells (continuous variable) were both associated with higher odds of achieving an objective response (P < 0.001 and P ¼ 0. Figure S3B , available at Annals of Oncology online) were highest and the corresponding P values were smallest for thresholds of percentage of positive cells closer to the 15% cut-off (maximum log-rank and HR thresholds of <27% versus 27% and <20% versus 20%, respectively). The test adjusting for multiplicity was not significant (P ¼ 0.052).
Kaplan-Meier estimates of PFS were calculated for subgroups of crizotinib-treated patients with low versus high ALK positivity defined by different thresholds (supplementary Figure S4 , available at Annals of Oncology online). When 20%, 25%, 35%, and 55% thresholds of ALK positivity were applied, the median PFS durations for crizotinib-treated patients above versus below the thresholds were 9.5 (95% CI 8.2-10.2) versus 4.3 months (95% CI 2.9-5.7), 9.6 (95% CI 8.3-10.8) versus 5.3 months (95% CI 4.0-6.7), 9.6 (95% CI 8.3-10.8) versus 6.8 months (95% CI 5.5-8.1), and 9.6 (95% CI 8.3-11.1) versus 7.7 months (95% CI 6.9-9.6), respectively. This showed that the differences in PFS for thresholds of percentage of ALK-positive cells were larger closer to the 15% cut-off; differences were substantially smaller at higher thresholds. Proportional hazards regression analysis of all crizotinib-treated patients further demonstrated that a higher percentage of ALK-positive cells evaluated as a continuous covariate was associated with longer PFS (P < 0.001; supplementary Figure S3 , available at Annals of Oncology online). 
Analysis of the percentage of ALK-positive cells and clinical outcomes in pooled crizotinib randomized trials
Magnitude of treatment arm difference in tumor response as a function of the percentage of ALK-positive cells. In a pooled analysis of the two randomized trials of crizotinib versus chemotherapy (PROFILE 1007 and 1014), the ORR was higher in the crizotinib versus chemotherapy arm for all but the subgroup with 15%-19% ALK-positive cells (n ¼ 23 versus n ¼ 13, respectively; Table 1 ). A pooled logistic regression analysis of tumor response in these trials compared crizotinib versus chemotherapy; the interaction model with the percentage of positive cells as a continuous covariate suggested that the benefit of crizotinib relative to chemotherapy was increased with a higher percentage of ALKpositive cells. However, the test for interaction was not significant (P ¼ 0.054).
Magnitude of treatment arm difference in PFS as a function of the percentage of ALK-positive cells. Similar to the tumor response interaction model, the pooled analysis of PFS in the randomized trials found that the benefit of crizotinib relative to chemotherapy was estimated to increase with a higher percentage of ALK-positive cells in the proportional hazards interaction model; however, the test for interaction was not significant (P ¼ 0.17).
Kaplan-Meier estimates of PFS by low and high ALK positivity in patients from the pooled randomized trials showed improved PFS with crizotinib compared with chemotherapy for patients with high percentages of ALK-positive cells, as expected ( Figure  2 ). Estimates in the subgroup near the threshold of ALK positivity (<20% ALK-positive cells) did not favor crizotinib. For instance, in a model including baseline characteristics, the PFS HR estimate for 15%-19% positive cells was 1.55 in favor of chemotherapy, with a 95% CI from 0.68 to 3.53. However, all these analyses in the subgroup of patients near the threshold of ALK positivity are limited by small sample sizes (n ¼ 36 pooled for crizotinib and chemotherapy).
The effect of ALK positivity thresholds was also assessed by individual study. In PROFILE 1007, discrimination by the percentage of ALK-positive cells was not evident (supplementary Table  S2 , available at Annals of Oncology online). Conversely, results from PROFILE 1014 indicated that there was a significant association between the percentage of ALK-positive cells and outcome (supplementary Table S2 , available at Annals of Oncology online).
Discussion
The percentage of ALK-positive cells by FISH in this large, pooled analysis of patients with NSCLC showed a bimodal distribution with distinct peaks of ALK positivity falling <5% and >50% for the two subgroups (Figure 1 ). This distribution reflects the biologic function of ALK as a dominant oncogene driver in NSCLC where all malignant cells in ALK-positive NSCLC diagnosed by FISH testing would be expected to contain ALK gene rearrangements, and all malignant cells in ALK-negative NSCLC would lack ALK gene rearrangements. The distribution of ALK positivity for these subgroups reflects potential biologic and technical factors that may contribute to a final result for ALK positivity and, therefore, ALK status based on the 15% cut-off. Biologic factors influencing detection and interpretation of a positive ALK probe break apart signal may include, for example, polysomy or atypical gene rearrangements. Technical factors include sectioning artifacts that limit the maximum possible number of positive split probe signals assessed on formalin-fixed, paraffin-embedded tissue sections, preanalytical factors impacting performance of the assay, and variability inherent in the manual interpretation and scoring of FISH signals (e.g. estimate of probe signal separation and classification of evaluated cells, including possible misclassification of normal cells as malignant cells) [8] . Among all screened patients, 68% were ALK negative and had a mean (standard deviation) ALK positivity of 3% (3%). Borderline cases with negative scores (10%-14% ALK-positive cells) represented only 2% of ALK-negative patients, in comparison to a previous report from a much smaller trial (overall, N ¼ 1426; ALK-positive patients, n ¼ 174; ALK-negative patients, n ¼ 1252), which suggested the frequency of patients with borderline ALK-negative scores (10%-15% ALK-positive cells) was 10% [9] . Differences in the frequency of borderline ALK-negative patients may reflect technical or biologic factors that differ between studies, including the patient population evaluated, test interpretation and scoring, and preanalytical conditions. Patients who are borderline ALK negative may represent an outlier group distinct from the overall ALK-negative population (e.g. reflecting the impact of polysomy on the interpretation of ALK FISH signals), a possibility that warrants further investigation. . In addition, when considering patients from the two randomized phase III trials, there was an observed lack of objective response and PFS benefit in this borderline ALK-positive population comparing patients randomized to crizotinib with those randomized to chemotherapy. These results, if valid, may reflect a greater proportion of patients who are either correctly classified as ALK positive by FISH but who are not sensitive to treatment with crizotinib for biologic reasons (e.g. intrinsic biologic resistance, tumor heterogeneity, alterations in the ALK gene that result in a positive signal of gene rearrangement by FISH but are not associated with oncogenic activity of the ALK protein), or who are incorrectly classified due to technical reasons impacting the predictive performance of the FISH test.
Orthogonal testing using alternative methods such as ALK immunohistochemistry (IHC) or next-generation sequencing would be useful to better understand the performance of the FISH test in this borderline positive group. Additional testing was not possible in the present analysis because of limited tissue availability or sample stability. However, recently reported results from IHC analysis of samples from patients enrolled in the PROFILE 1014 study demonstrated that, while overall concordance between FISH and IHC was high (94%; n ¼ 933), among 25 patients with discordant FISH-positive/IHC-negative results, the median ALK positivity by FISH was 22% when compared with the overall median ALK positivity of 58%, with 14 of the 25 discordant cases exhibiting ALK positivity of 25% by FISH [10] . Among the six FISH-positive/IHC-negative discordant patients who were treated with crizotinib, two patients who exhibited a partial response had FISH scores of 67% and 72% and four patients who exhibited either progressive or stable disease (two each) had FISH scores in the borderline positive range (15%-19%) [10] . Together with the present data, these results suggest that, while a significant proportion of patients with borderline positive FISH results may benefit from treatment with crizotinib, additional orthogonal ALK testing may be useful to more accurately define their true predictive ALK status.
In addition to the absence of alternative ALK testing methods, variability in the distribution of the number of prior systemic therapies within ALK-positive groups could have played a role in this analysis where pooling results from treatment-naïve patients and previously treated patients may have introduced variability into the dataset, as ORR was higher among patients treated in the first-line setting compared with those who had received previous treatments (74% versus 65%, respectively) [11, 12] . The number of prior systemic therapies may have also impacted analysis of PFS, as the median PFS of crizotinib-treated patients was lower in previously treated patients compared with treatment-naïve patients (7.7 versus 10.9 months, respectively) [11, 12] . However, despite this limitation, pooling of the data was considered to be appropriate given that, with randomized data, the number of crizotinib-treated patients in specifically defined subsets, such as patients in the borderline positive category of 15%-19% ALKpositive cells, became relatively small and the results difficult to interpret.
Overall, these results further support the clinical utility of ALK FISH testing that employs a cut-off of 15% ALK positivity in identifying patients with ALK-positive NSCLC who benefit from treatment with crizotinib. While these data specifically address treatment with crizotinib, there is no overt biologic reason why these results would not also be relevant to treatment with any other ALK inhibitor.
